Navigation Links
Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
Date:2/19/2013

SAN DIEGO, Feb. 19, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2012 on Monday, February 25, 2013 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost , Ph.D., President and Chief Executive Officer, will lead the call. On the same date pre-market, Halozyme will release financial results for the fourth quarter and year-ended December 31, 2012.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using replay ID number 409638.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Investor Contact:
Kurt Gustafson
Halozyme Therapeutics
858-704-8272
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
310-633-9434
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
6. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
7. BioMed Realty Trust Declares Fourth Quarter 2011 Common Stock and Preferred Stock Dividends
8. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
9. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
10. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
11. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... A new study ... in frozen and fresh in vitro fertilization (IVF) transfer cycles. The ... IVF success. , After comparing the results from the fresh and frozen transfer ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder ... local San Diego Rotary Club. The event entitled “Stem Cells and ... had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... applications consulting for microscopy and surface analysis, Nanoscience Instruments is now expanding ... offers a broad range of contract analysis services for advanced applications. Services ...
Breaking Biology Technology:
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
Breaking Biology News(10 mins):